Evidence map›Paper›PMID 28687749›Full record

ArticleScientific reports2017

Inhibition of highly pathogenic avian influenza (HPAI) virus by a peptide derived from vFLIP through its direct destabilization of viruses.

Ho-Jin Moon, Chamilani Nikapitiya, Hyun-Cheol Lee, Min-Eun Park, Jae-Hoon Kim, Tae-Hwan Kim, Ji-Eun Yoon, Won-Kyung Cho, Jin Yeul Ma, Chul-Joong Kim and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Leveraging the therapeutic, biological, and self-assembling potential of peptides for the treatment of viral infections.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Role of Autophagy in Lung Inflammation.Frontiers in immunology · 2020
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Ho-Jin MoonCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Chamilani NikapitiyaCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Hyun-Cheol LeeCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Min-Eun ParkCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Jae-Hoon KimCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Tae-Hwan KimCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Ji-Eun YoonCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Won-Kyung ChoKorean Medicine (KM) Application Centre, Korea Institute of Oriental Medicine, Daegu, 41062, Republic of Korea.
Jin Yeul MaKorean Medicine (KM) Application Centre, Korea Institute of Oriental Medicine, Daegu, 41062, Republic of Korea.
Chul-Joong KimCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea.
Jae U JungDepartment of Molecular Microbiology and Immunology, University of Southern California, Keck School of Medicine, Los Angeles, CA, USA.
Jong-Soo LeeCollege of Veterinary Medicine, Chungnam National University, Daejeon, Republic of Korea. jongsool@cnu.ac.kr.
Chungnam National University · KRKorea Institute of Oriental Medicine · KRAnimal and Plant Quarantine Agency · KRUniversity of Southern California · US

Funding

Molecular Basis of KSHV oncogenesisR35CA200422 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2016 to 2022
$6.1M
Role of viral BCI-2 mediated anti-apoptosis and-autophagyR01AI073099 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JUNG, JAE U · 2007 to 2017
$4.3M
NCI NIH HHS R35 CA200422NIAID NIH HHS R01 AI073099
6 · The paper itself

Abstract

The antiviral activities of synthesized Kα2-helix peptide, which was derived from the viral FLICE-like inhibitor protein (vFLIP) of Kaposi's sarcoma-associated herpesvirus (KSHV), against influenza A virus (IAV) were investigated in vitro and in vivo, and mechanisms of action were suggested. In addition to the robust autophagy activity of the Kα2-helix peptide, the present study showed that treatment with the Kα2 peptide fused with the TAT peptide significantly inhibited IAV replication and transmission. Moreover, TAT-Kα2 peptide protected the mice, that were challenged with lethal doses of highly pathogenic influenza A H5N1 or H1N1 viruses. Mechanistically, we found that TAT-Kα2 peptide destabilized the viral membranes, depending on their lipid composition of the viral envelop. In addition to IAV, the Kα2 peptide inhibited infections with enveloped viruses, such as Vesicular Stomatitis Virus (VSV) and Respiratory Syncytial Virus (RSV), without cytotoxicity. These results suggest that TAT-Kα2 peptide is a potential antiviral agent for controlling emerging or re-emerging enveloped viruses, particularly diverse subtypes of IAVs.

Indexed as

AnimalsAntiviral AgentsDisease Models, AnimalDogsInfluenza A virusLungMadin Darby Canine Kidney CellsMice, Inbred BALB COligopeptidesOrthomyxoviridae InfectionsRespiratory Syncytial VirusesSurvival AnalysisTreatment OutcomeVesiculovirusViral LoadViral ProteinsAntiviral AgentsOligopeptidesviral FLIP protein, Human herpesvirus 8Viral Proteins

Identifiers

PMID28687749
PMCPMC5501782
OpenAlexW2725621871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.